In8Bio (INAB) Operating Income (2020 - 2026)
In8Bio (INAB) posted Operating Income of -$5.1 million for Q1 2026, down 2.99% sequentially from -$4.9 million in Q4 2025, and up 8.29% YoY from -$4.7 million in Q1 2025.
In8Bio (INAB) Operating Income (2020 - 2026) Analysis & Trends
In8Bio has reported Operating Income for 7 years, with the latest figure at -$5.1 million in Q1 2026.
- Quarterly Operating Income rose 8.29% year-over-year to -$5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.0 million (up 30.79% YoY) and the FY2025 annual result came in at -$19.4 million, up 36.13% from the prior year.
- Operating Income eased to -$5.1 million in Q1 2026 per INAB's latest filing, from -$4.9 million in the prior quarter.
- Over five years, Operating Income peaked at -$3.9 million in Q3 2025 and troughed at -$8.6 million in Q2 2024.
- A 5-year average of -$6.7 million and a median of -$7.2 million in 2023 frame the typical range for Operating Income.
- The sharpest annual moves came in 2022 and 2025: Operating Income slumped 160.05% in 2022, then jumped 45.61% in 2025.
- Over 5 years, Operating Income stood at -$7.8 million in 2022, then rose by 2.56% to -$7.6 million in 2023, then rose by 18.93% to -$6.2 million in 2024, then rose by 19.77% to -$4.9 million in 2025, then slipped by 2.99% to -$5.1 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$5.1 million, -$4.9 million, and -$3.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | In8Bio | 22.97 Mn | 22.97 Mn | - | -4.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.78 Mn |
| Mar 31, 2026 | -5.09 Mn |
| Dec 31, 2025 | -4.94 Mn |
| Sep 30, 2025 | -3.85 Mn |
| Jun 30, 2025 | -5.09 Mn |
| Mar 31, 2025 | -5.55 Mn |
| Dec 31, 2024 | -6.16 Mn |
| Sep 30, 2024 | -7.09 Mn |
| Jun 30, 2024 | -8.63 Mn |
| Mar 31, 2024 | -8.56 Mn |
| Dec 31, 2023 | -7.60 Mn |
| Sep 30, 2023 | -7.17 Mn |
| Jun 30, 2023 | -7.72 Mn |
| Mar 31, 2023 | -7.53 Mn |
| Dec 31, 2022 | -7.80 Mn |
| Sep 30, 2022 | -7.40 Mn |
| Jun 30, 2022 | -7.18 Mn |
| Mar 31, 2022 | -6.15 Mn |
| Dec 31, 2021 | -5.85 Mn |
| Sep 30, 2021 | -3.39 Mn |